Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

Background: The oral anti-janus kinase 1 inhibitor upadacitinib has shown a good efficacy-safety profile in the treatment of moderate-to-severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far.ObjectivesTo evaluate the efficacy and s...

ver descrição completa

Detalhes bibliográficos
Autores: Batalla, Ana, Suh‐Oh, Hae Jin, Carretero Hernández, Gregorio, Miquel Miquel, Javier, Botella Estrada, Rafael, Martorell Calatayud, Antonio, Sanz Motilva, Virginia, Figueras Nart, Ignasi, Flórez, Angeles
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/214369
Acesso em linha:https://hdl.handle.net/2445/214369
Access Level:acceso abierto
Palavra-chave:Dermatitis atòpica
Assaigs clínics
Clinical trials
Atopic dermatitis
id ES_56c5e03d7e455227e19bc883affe1164
oai_identifier_str oai:recercat.cat:2445/214369
network_acronym_str ES
network_name_str España
repository_id_str
spelling Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitisBatalla, AnaSuh‐Oh, Hae JinCarretero Hernández, GregorioMiquel Miquel, JavierBotella Estrada, RafaelMartorell Calatayud, AntonioSanz Motilva, VirginiaFigueras Nart, IgnasiFlórez, AngelesDermatitis atòpicaAssaigs clínicsClinical trialsAtopic dermatitisBackground: The oral anti-janus kinase 1 inhibitor upadacitinib has shown a good efficacy-safety profile in the treatment of moderate-to-severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far.ObjectivesTo evaluate the efficacy and safety of upadactinib in clinical practice.MethodsAn observational and multicentric study was conducted. Inclusion criteria consisted of patients who had previously received upadacitinib in the clinical trial M19-850 and continued treatment with upadacitinib (15 mg or 30 mg) under daily clinical practice conditions for 12 months. Demographic data, characteristics of AD, treatment response and adverse events were recorded. Preliminary results at 24-week follow-up are herein presented.ResultsA total of 26 patients (61.54% males, mean age: 35.58 years) were included in the study; of these, 92.31% received upadacitinib 30 mg at baseline. At 24 weeks, mean values of Eczema Area and Severity Index and body surface area were 2.26 and 2.37%, respectively, 82.35% of the patients reached the Investigator's Global Assessment 0/1 and the mean value of peak pruritus numerical rating scale was 1.74. Adverse events were present in 19.23% of the cases, causing one definitive treatment interruption (due to herpes zoster) and two temporary treatment discontinuations (due to temporary elevation of creatine kinase).ConclusionsThese data support the maintenance of the efficacy of upadacitinib at 24-week posttrial follow-up, with no unexpected safety concerns. More real-world data are needed to confirm these results.Wiley2024202420232024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion5 p.application/pdfhttps://hdl.handle.net/2445/214369Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1002/jvc2.179JEADV Clinical Practice, 2023, vol. 2, num. 3, p. 571-575https://doi.org/10.1002/jvc2.179cc by (c) Batalla, Ana et al., 2023http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2143692026-05-29T05:05:01Z
dc.title.none.fl_str_mv Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
title Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
spellingShingle Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
Batalla, Ana
Dermatitis atòpica
Assaigs clínics
Clinical trials
Atopic dermatitis
title_short Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
title_full Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
title_fullStr Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
title_full_unstemmed Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
title_sort Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
dc.creator.none.fl_str_mv Batalla, Ana
Suh‐Oh, Hae Jin
Carretero Hernández, Gregorio
Miquel Miquel, Javier
Botella Estrada, Rafael
Martorell Calatayud, Antonio
Sanz Motilva, Virginia
Figueras Nart, Ignasi
Flórez, Angeles
author Batalla, Ana
author_facet Batalla, Ana
Suh‐Oh, Hae Jin
Carretero Hernández, Gregorio
Miquel Miquel, Javier
Botella Estrada, Rafael
Martorell Calatayud, Antonio
Sanz Motilva, Virginia
Figueras Nart, Ignasi
Flórez, Angeles
author_role author
author2 Suh‐Oh, Hae Jin
Carretero Hernández, Gregorio
Miquel Miquel, Javier
Botella Estrada, Rafael
Martorell Calatayud, Antonio
Sanz Motilva, Virginia
Figueras Nart, Ignasi
Flórez, Angeles
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Dermatitis atòpica
Assaigs clínics
Clinical trials
Atopic dermatitis
topic Dermatitis atòpica
Assaigs clínics
Clinical trials
Atopic dermatitis
description Background: The oral anti-janus kinase 1 inhibitor upadacitinib has shown a good efficacy-safety profile in the treatment of moderate-to-severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far.ObjectivesTo evaluate the efficacy and safety of upadactinib in clinical practice.MethodsAn observational and multicentric study was conducted. Inclusion criteria consisted of patients who had previously received upadacitinib in the clinical trial M19-850 and continued treatment with upadacitinib (15 mg or 30 mg) under daily clinical practice conditions for 12 months. Demographic data, characteristics of AD, treatment response and adverse events were recorded. Preliminary results at 24-week follow-up are herein presented.ResultsA total of 26 patients (61.54% males, mean age: 35.58 years) were included in the study; of these, 92.31% received upadacitinib 30 mg at baseline. At 24 weeks, mean values of Eczema Area and Severity Index and body surface area were 2.26 and 2.37%, respectively, 82.35% of the patients reached the Investigator's Global Assessment 0/1 and the mean value of peak pruritus numerical rating scale was 1.74. Adverse events were present in 19.23% of the cases, causing one definitive treatment interruption (due to herpes zoster) and two temporary treatment discontinuations (due to temporary elevation of creatine kinase).ConclusionsThese data support the maintenance of the efficacy of upadacitinib at 24-week posttrial follow-up, with no unexpected safety concerns. More real-world data are needed to confirm these results.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/214369
url https://hdl.handle.net/2445/214369
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1002/jvc2.179
JEADV Clinical Practice, 2023, vol. 2, num. 3, p. 571-575
https://doi.org/10.1002/jvc2.179
dc.rights.none.fl_str_mv cc by (c) Batalla, Ana et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Batalla, Ana et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 5 p.
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408403772669952
score 15,198674

Registos relacionados